Aptamer Group (APTA)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

1.20p
   
  • Change Today:
      0.20p
  • 52 Week High: 1.25p
  • 52 Week Low: 0.21p
  • Currency: UK Pounds
  • Shares Issued: 2,696.98m
  • Volume: 96,561,202
  • Market Cap: £32.36m

Aptamer gets more commissioned work from Unilever

By Josh White

Date: Monday 21 Jul 2025

LONDON (ShareCast) - (Sharecast News) - Aptamer Group announced on Monday that it has received additional commissioned work from Unilever to support the ongoing development of its proprietary Optimer binders for use in deodorant products.
The AIM-traded firm said the new paid work package, part of an existing collaboration between the two companies, would fund expanded testing and development of Aptamer's synthetic binders, which are designed to inhibit C-S Lyase, the key enzyme in skin bacteria responsible for body odour.

It said the technology had demonstrated strong performance in laboratory settings, with recent tests showing 72-hour stability in skin samples that matched or exceeded leading commercial deodorants.

Aptamer said the collaboration, which started in 2022, had now moved into a more advanced phase.

The additional funding from Unilever would support comprehensive stability testing under varied conditions, with the goal of progressing to on-person trials in the near term.

"We are thrilled with the continued momentum in our Unilever collaboration, which highlights the real-world potential of our Optimer platform," said Dr Arron Tolley, chief executive of Aptamer Group.

"This latest paid extension for expanded stability testing is a critical advancement toward on-person trials and validates the superior performance we have achieved so far.

"Partnering with a powerhouse like Unilever not only accelerates our technology's path to market but also opens doors to broader applications in personal care and beyond."

Unilever controls more than 30% of the global deodorant market, significantly ahead of its nearest competitor at around 10%.

With the sector forecast to grow at a compound annual rate of 4.5% over the next five years, Aptamer said it saw substantial commercial potential for its Optimer technology in the personal care space.

At 1225 BST, shares in Aptamer Group were down 1.05% at 0.38p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Aptamer Group Market Data

Currency UK Pounds
Share Price 1.20p
Change Today 0.20p
% Change 20.00 %
52 Week High 1.25p
52 Week Low 0.21p
Volume 96,561,202
Shares Issued 2,696.98m
Market Cap £32.36m

Aptamer Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.62% below the market average64.62% below the market average64.62% below the market average64.62% below the market average64.62% below the market average
85.37% below the sector average85.37% below the sector average85.37% below the sector average85.37% below the sector average85.37% below the sector average
Price Trend
53.49% above the market average53.49% above the market average53.49% above the market average53.49% above the market average53.49% above the market average
72.73% above the sector average72.73% above the sector average72.73% above the sector average72.73% above the sector average72.73% above the sector average
Income Not Available
Growth
41.68% below the market average41.68% below the market average41.68% below the market average41.68% below the market average41.68% below the market average
44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average

Aptamer Group Dividends

No dividends found

Trades for 29-Aug-2025

Time Volume / Share Price
16:14 846,045 @ 1.21p
15:57 1,000,000 @ 1.16p
15:55 1,000,000 @ 1.19p
15:52 941,747 @ 1.19p
15:47 807,127 @ 1.18p

Aptamer Group Key Personnel

CEO Arron Tolley
CFO Andrew Rapson

Top of Page